Enigma Signs Licence Agreement with the UK Defence Science and Technology Laboratory
News Aug 24, 2007
The worldwide licence covers a broad range of technologies, including Pyrostart, ResonSense and Temperature Control, which are important elements of Enigma’s real-time PCR systems. These PCR systems are being developed for the detection and identification of infectious organisms, such as bacteria and viruses, in clinical, environmental and biological samples. This new agreement follows the initial licence agreement that Enigma signed with Dstl in 2004.
The new licence agreement, which will remain in place until 2026, is an important development for Enigma as it will enable the Company to sub-licence any of the technologies covered by the agreement to potential partners and collaborators. The ability to sub-licence the technologies covers both PCR and non-PCR applications.
In addition, it will enable Enigma to develop its own patent portfolio, as any improvement that it makes to any of the technologies covered by this agreement will be able to be patented by the Company. As part of the agreement, Enigma will also gain ownership of a number of trademarks.
The agreement covers 25 patents and patent applications, which with effect from 13 August 2007, will be maintained and managed by Enigma. These patents were previously the responsibility of Dstl.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019